<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00089713</url>
  </required_header>
  <id_info>
    <org_study_id>ALT-711-0320</org_study_id>
    <nct_id>NCT00089713</nct_id>
  </id_info>
  <brief_title>Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA)</brief_title>
  <official_title>Effect of ALT-711 in Combination With Fixed-Dose Hydrochlorothiazide Therapy on Systolic Blood Pressure in Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synvista Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synvista Therapeutics, Inc</source>
  <brief_summary>
    <textblock>
      This study comprises a 3- to 6-week hydrochlorothiazide run in phase, followed by a 12 week
      double-blind treatment phase, followed by a 2 week single-blind follow-up hydrochlorothiazide
      treatment phase. The combined total duration of patient participation is approximately 17-20
      weeks. Four double-blind treatment groups approximately equal in size (98) will comprise the
      study population: placebo or various alagebrium dose groups (10, 50, or 150 mg/day).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>March 2004</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>392</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alagebrium chloride (ALT-711)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women at least 45 years of age with uncontrolled systolic hypertension measured
             by office cuff and by an ambulatory blood pressure monitoring device

          -  Willingness to be taken off any current antihypertensive treatment to be placed on
             hydrochlorothiazide in combination with study medication.

        Exclusion Criteria:

          -  Any significant history, systemic illnesses, or medical condition(s) that could lead
             to difficulty complying with the protocol or that could confound interpretation of the
             data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milan Kovacevic, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Synvista Therapeutics, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alteon Inc.</name>
      <address>
        <city>Parsippany</city>
        <state>New Jersey</state>
        <zip>07054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, Lakatta EG. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation. 2001 Sep 25;104(13):1464-70.</citation>
    <PMID>11571237</PMID>
  </reference>
  <reference>
    <citation>Asif M, Egan J, Vasan S, Jyothirmayi GN, Masurekar MR, Lopez S, Williams C, Torres RL, Wagle D, Ulrich P, Cerami A, Brines M, Regan TJ. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2809-13. Erratum in: Proc Natl Acad Sci U S A 2000 May 9;97(10):5679.</citation>
    <PMID>10706607</PMID>
  </reference>
  <reference>
    <citation>Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN, Vasan S, Egan JJ, Ulrich P, Cerami A, LÃ©vy BI. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4630-4.</citation>
    <PMID>9539789</PMID>
  </reference>
  <reference>
    <citation>Vaitkevicius PV, Lane M, Spurgeon H, Ingram DK, Roth GS, Egan JJ, Vasan S, Wagle DR, Ulrich P, Brines M, Wuerth JP, Cerami A, Lakatta EG. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1171-5.</citation>
    <PMID>11158613</PMID>
  </reference>
  <reference>
    <citation>Chobanian AV. Control of hypertension--an important national priority. N Engl J Med. 2001 Aug 16;345(7):534-5.</citation>
    <PMID>11519509</PMID>
  </reference>
  <reference>
    <citation>Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001 Aug 16;345(7):479-86. Erratum in: N Engl J Med 2002 Feb 14;346(7):544.</citation>
    <PMID>11519501</PMID>
  </reference>
  <reference>
    <citation>Wilkinson IB, Webb Christison DJ, Cockcroft JR. Isolated systolic hypertension: a radical rethink. It's a risk factor that needs treatment, especially in the over 50s. BMJ. 2000 Jun 24;320(7251):1685.</citation>
    <PMID>10864525</PMID>
  </reference>
  <reference>
    <citation>Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 1986 Jun 27;232(4758):1629-32.</citation>
    <PMID>3487117</PMID>
  </reference>
  <reference>
    <citation>Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992 Jan;152(1):56-64.</citation>
    <PMID>1728930</PMID>
  </reference>
  <reference>
    <citation>Liu J, Masurekar MR, Vatner DE, Jyothirmayi GN, Regan TJ, Vatner SF, Meggs LG, Malhotra A. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am J Physiol Heart Circ Physiol. 2003 Dec;285(6):H2587-91. Epub 2003 Aug 28.</citation>
    <PMID>12946933</PMID>
  </reference>
  <verification_date>June 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2004</study_first_submitted>
  <study_first_submitted_qc>August 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2004</study_first_posted>
  <last_update_submitted>February 5, 2010</last_update_submitted>
  <last_update_submitted_qc>February 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2010</last_update_posted>
  <keyword>antihypertensive agents/therapeutic use</keyword>
  <keyword>hypertension/drug therapy</keyword>
  <keyword>blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

